Intestinal Obstruction disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INT070 MIFTS: 58	Intestinal Obstruction Categories: Fetal diseases, Gastrointestinal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Intestinal Obstruction

MalaCards integrated aliases for Intestinal Obstruction:

Name: Intestinal Obstruction ¹¹ ²⁸ ⁵³ ⁵ ⁴¹ ⁴³ ¹⁴ ⁷¹

Inspissated Milk Syndrome ³³

Milk Curd Syndrome ³³

Classifications:

MalaCards categories:
Global: Fetal diseases Rare diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain conditions originating in the perinatal period

Digestive system disorders of fetus and newborn

Other intestinal obstruction of newborn

Intestinal obstruction due to inspissated milk

ICD11: ³³

Certain conditions originating in the perinatal period

Digestive system disorders of fetus or newborn

Intestinal obstruction of newborn

Intestinal obstruction due to inspissated milk

External Ids:

Disease Ontology ¹¹ DOID:8437

ICD9CM ³⁴ 560.9

MeSH ⁴³ D007415

NCIt ⁴⁹ C9175

SNOMED-CT ⁶⁸ 81060008

ICD10 ³¹ P76.2

ICD11 ³³ 1863733515

UMLS ⁷¹ C0021843

Sources

Summaries for Intestinal Obstruction

MedlinePlus: ⁴¹ An intestinal obstruction occurs when food or stool cannot move through the intestines. The obstruction can be complete or partial. There are many causes. The most common are adhesions, hernias, cancers, and certain medicines. Symptoms include: Severe abdominal pain or cramping Vomiting Bloating Loud bowel sounds Swelling of the abdomen Inability to pass gas Constipation A complete intestinal obstruction is a medical emergency. It often requires surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Intestinal Obstruction, also known as inspissated milk syndrome, is related to ileus and hirschsprung disease 1, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Intestinal Obstruction is SLC26A3 (Solute Carrier Family 26 Member 3), and among its related pathways/superpathways are Signal Transduction and Cytoskeletal Signaling. The drugs Dexmedetomidine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, small intestine and colon, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Sources

Related Diseases for Intestinal Obstruction

Diseases in the Intestinal Obstruction family:

Intestinal Pseudo-Obstruction

Diseases related to Intestinal Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 900)

#	Related Disease	Score	Top Affiliating Genes
1	ileus	32.4	GUCY2C CRP CFTR
2	hirschsprung disease 1	32.1	RET NRTN GDNF EDNRB EDN3 ACTG2
3	intestinal pseudo-obstruction	31.7	SGO1 RET FLNA EDNRB EDN3 CFTR
4	rectal benign neoplasm	31.2	KRT7 KRT20 CDX2
5	lymphangioma	31.1	KRT7 KRT20 CDX2 CD8A
6	colonic benign neoplasm	31.0	KRT7 KRT20 CDX2 CD8A
7	intestinal perforation	31.0	NOD2 KRT7 CRP CD8A
8	intestinal tuberculosis	30.9	NOD2 CRP
9	pseudomyxoma peritonei	30.8	KRT7 KRT20 CDX2
10	diarrhea	30.7	SLC26A3 NOD2 MVK GUCY2C CFTR
11	familial mediterranean fever	30.7	NOD2 MVK CRP
12	small intestine cancer	30.7	KRT7 KRT20 CDX2
13	megacolon	30.7	RET NRTN GDNF EDNRB EDN3
14	appendix adenocarcinoma	30.6	KRT7 KRT20 CDX2
15	cystic teratoma	30.6	KRT7 KRT20 CDX2
16	neuroendocrine tumor	30.6	RET MTOR KRT20 CDX2
17	megacystis-microcolon-intestinal hypoperistalsis syndrome 1	30.6	SGO1 FLNA ACTG2
18	enterocolitis	30.4	NOD2 CRP
19	hemorrhoid	30.4	KRT7 KRT20 CRP
20	adenoma	30.4	SLC26A3 RET KRT7 KRT20 CDX2
21	small intestine adenocarcinoma	30.4	KRT7 CDX2
22	cholangiocarcinoma	30.4	MTOR KRT7 KRT20 CDX2
23	jejunal adenocarcinoma	30.3	KRT7 CDX2
24	hydronephrosis	30.3	KRT7 CRP ACTG2
25	sigmoid neoplasm	30.3	KRT7 KRT20 CDX2
26	signet ring cell adenocarcinoma	30.3	KRT7 KRT20 CDX2
27	mucinous adenocarcinoma	30.3	KRT7 KRT20 CDX2
28	behcet syndrome	30.3	NOD2 MVK CRP CD8A
29	ascending colon cancer	30.3	KRT7 CDX2
30	ampulla of vater adenocarcinoma	30.3	KRT7 KRT20 CDX2
31	mucinous cystadenocarcinoma	30.3	KRT7 KRT20 CDX2
32	benign teratoma	30.3	KRT7 KRT20 CDX2
33	cystic kidney disease	30.2	MTOR EDNRB CRP CFTR
34	cystitis	30.2	KRT7 KRT20 CRP
35	abdominal tuberculosis	30.2	NOD2 CRP CD8A
36	exanthem	30.1	MTOR CRP CD8A
37	pheochromocytoma	30.1	RET KRT7 GDNF EDN3 CRP
38	cholangitis	30.0	NOD2 KRT7 CRP CFTR
39	vesicoureteral reflux	29.9	RET GDNF CRP
40	meconium ileus	11.7
41	volvulus of midgut	11.3
42	paralytic ileus	11.2
43	peritonitis	11.2
44	colonic atresia	11.2
45	intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked	11.2
46	ascaris lumbricoides infection	11.2
47	omphalomesenteric cyst	11.2
48	santos mateus leal syndrome	11.2
49	crohn's disease	11.1
50	jejunal atresia	11.1

Comorbidity relations with Intestinal Obstruction via Phenotypic Disease Network (PDN): (show top 50) (show all 57)

Active Peptic Ulcer Disease	Acute Cystitis
Acute Kidney Failure	Acute Pancreatitis
Acute Vascular Insufficiency of Intestine	Anxiety
Ascending Colon Cancer	Bronchitis
Candidiasis	Cecal Benign Neoplasm
Cervical Cancer	Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease	Chylomicron Retention Disease
Colorectal Cancer	Crohn's Disease
Decubitus Ulcer	Deficiency Anemia
Descending Colon Cancer	Enterovesical Fistula
Esophageal Disease	Esophagitis
Familial Atrial Fibrillation	Gastric Cancer
Gastrointestinal System Cancer	Generalized Atherosclerosis
Heart Disease	Hepatic Flexure Cancer
Hydronephrosis	Hypertension, Essential
Hypothyroidism	Inflammatory Bowel Disease 1
Intestinal Disease	Intestinal Perforation
Iron Deficiency Anemia	Irritable Bowel Syndrome
Jejunal Cancer	Kidney Disease
Marasmus	Neutropenia
Osteoporosis	Ovarian Cancer
Pancreatic Cancer	Pancreatitis, Hereditary
Paralytic Ileus	Peritonitis
Postgastrectomy Syndrome	Protein-Energy Malnutrition
Radiation Cystitis	Rectosigmoid Junction Neoplasm

Graphical network of the top 20 diseases related to Intestinal Obstruction:

Sources

Symptoms & Phenotypes for Intestinal Obstruction

UMLS symptoms related to Intestinal Obstruction:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.17	ACTG2 CD8A CDX2 CFTR CRP EDN3
2	no effect	GR00402-S-2	10.17	ACTG2 CDX2 CFTR CRP EDN3 EDNRB

MGI Mouse Phenotypes related to Intestinal Obstruction:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.17	ACTG2 CDX2 CFTR CRP EDNRB FLNA
2	endocrine/exocrine gland	MP:0005379	10.03	CD8A CDX2 CFTR EDNRB GDNF MTOR
3	digestive/alimentary	MP:0005381	9.93	CDX2 CFTR EDN3 EDNRB FLNA GDNF
4	cellular	MP:0005384	9.77	CD8A CDX2 CFTR EDNRB FLNA GDNF
5	mortality/aging	MP:0010768	9.5	CD8A CDX2 CFTR EDN3 EDNRB FLNA

Sources

Drugs & Therapeutics for Intestinal Obstruction

Drugs for Intestinal Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Somatostatin

Approved, Investigational

Phase 4

38916-34-6, 51110-01-1

53481605 16129706

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Hypnotics and Sedatives

Phase 4

Analgesics, Non-Narcotic

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Anesthetics, Dissociative

Phase 4

Neuromuscular Nondepolarizing Agents

Phase 4

Neuromuscular Blocking Agents

Phase 4

Anesthetics

Phase 4

Analgesics

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Anti-Inflammatory Agents

Phase 4

Narcotics

Phase 4

Anesthetics, Local

Phase 4

Analgesics, Opioid

Phase 4

Naloxone

Approved, Vet_approved

Phase 3

465-65-6

5284596

Lanreotide

Approved

Phase 3

108736-35-2

71349 6918011

Phenobarbital

Approved, Investigational

Phase 3

50-06-6

4763

Metronidazole

Approved

Phase 3

443-48-1, 69198-10-3

4173

Amoxicillin

Approved, Vet_approved

Phase 3

26787-78-0

33613

Cefuroxime

Approved

Phase 3

55268-75-2

5479529

Fluconazole

Approved, Investigational

Phase 3

86386-73-4

3365

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clavulanic acid

Approved, Vet_approved

Phase 3

58001-44-8

5280980

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Narcotic Antagonists

Phase 3

Antibiotics, Antitubercular

Phase 3

Anti-Bacterial Agents

Phase 3

Anti-Infective Agents

Phase 3

Anticonvulsants

Phase 3

GABA Modulators

Phase 3

Antiprotozoal Agents

Phase 3

Antiparasitic Agents

Phase 3

Cefuroxime axetil

Phase 3

3379942

beta-Lactamase Inhibitors

Phase 3

Interventional clinical trials:

(show top 50) (show all 117)

#	Name	Status	NCT ID	Phase	Drugs
1	Ketofol vs Dexmedetomidine for Preventing Post-operative Delirium in Elderly Patients Undergoing Intestinal Obstruction Surgeries. A Randomized Controlled Study	Completed	NCT04816162	Phase 4	ketofol;dexmedetomidine
2	Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery	Completed	NCT00531739	Phase 4
3	Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction	Completed	NCT00389116	Phase 4	gastrograffin;water
4	Gastrografin Use in Small Bowel Obstruction Caused by Adherences	Completed	NCT00601809	Phase 4	Gastrografin®: G
5	Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery	Completed	NCT02812186	Phase 4	Rocuronium
6	Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction	Completed	NCT01082627	Phase 4	Somatostatin
7	A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy	Completed	NCT01507246	Phase 4	IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
8	The Effects of Preoperative High-dose Dexamethasone on Inflammatory Response and Recovery After Emergency Laparotomy, a Randomized, Double-blind, Placebo-controlled Clinical Trial - AHA STEROID TRIAL	Recruiting	NCT04791566	Phase 4	Dexamethasone 1 mg/kg;Physiologic saline
9	A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)	Terminated	NCT02058290	Phase 4	IV morphine sulfate or Sponsor-approved equivalent;EXPAREL
10	A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy	Terminated	NCT01507233	Phase 4	IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
11	A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy	Terminated	NCT01507220	Phase 4	morphine sulfate;bupivacaine liposome extended-release injectable suspension
12	The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients.	Withdrawn	NCT03334578	Phase 4	Gastrografin
13	Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer.	Unknown status	NCT02198898	Phase 3
14	Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial	Unknown status	NCT00164879	Phase 3
15	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-malignant Pain or Malignant Pain	Unknown status	NCT00020605	Phase 3	naloxone hydrochloride
16	Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting	Completed	NCT01834430	Phase 3
17	Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial.	Completed	NCT00758186	Phase 3
18	Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients.	Completed	NCT00216372	Phase 3	Lanreotide (microparticle formulation)
19	Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial	Completed	NCT00529412	Phase 3
20	Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery	Completed	NCT00140868	Phase 3
21	Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis	Completed	NCT01524081	Phase 3	Metronidazole, Cefuroxime;Amoxicillin (+ clavulanic acid) and Fluconazole;Placebo
22	The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study	Recruiting	NCT03573921	Phase 2, Phase 3	Gastrograﬁn
23	A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy	Withdrawn	NCT01473290	Phase 3
24	An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction	Completed	NCT02275338	Phase 2	Lanreotide Autogel
25	Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis	Completed	NCT00332696	Phase 2	Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
26	Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients	Completed	NCT01076803	Phase 2	Lanreotide (acetate)
27	Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study	Completed	NCT00004895	Phase 2	octreotide acetate
28	A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy	Completed	NCT00004911	Phase 1, Phase 2
29	A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy	Completed	NCT00004910	Phase 1, Phase 2
30	A Phase II, Non-Randomized, Multi-Cohort Trial of Docetaxel, Oxaliplatin and 5-Fluorouracil in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis and Inoperable Malignant Bowel Obstruction	Recruiting	NCT04840264	Phase 2	Docetaxel;Oxaliplatin;5Fluorouracil
31	A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)	Terminated	NCT02365584	Phase 2	lanreotide (Autogel formulation)
32	Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction	Terminated	NCT02692638	Phase 2
33	Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center	Terminated	NCT04027348	Phase 2	Dexamethasone;Metoclopramide;Octreotide
34	Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction	Terminated	NCT01083537	Phase 1, Phase 2	Cisplatin;Paclitaxel
35	Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects	Completed	NCT01596777	Phase 1	Loperamide;Loperamide placebo;Methylnaltrexone placebo;Methylnaltrexone 12 mg sc.;Methylnaltrexone IR capsule;Methylnaltrexone ER capsule;Sulfasalazine
36	Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects.	Completed	NCT01596764	Phase 1	Loperamide placebo;Loperamide;Sulfasalazine;Placebo of MNTX and NLX;Naloxone;Methylnaltrexone
37	Therapeutic Oxygen for Gastrointestinal Atony (TOGA): Pilot Trial - Management of Acute Colonic Pseudo-Obstruction With Oxygen Supplementation	Completed	NCT03386136	Phase 1	100% Oxygen
38	Hypertonic Saline 3% Compared to Hypertonic Saline 1.8% for Fluid Management of Intestinal Obstruction Surgery	Unknown status	NCT03741257		Hypertonic saline
39	Ostomy in Continuity or Conventional Ileostomy for Complex Pediatric Intestinal Diseases: a Retrospective Multicentric Analysis	Unknown status	NCT04213976
40	Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients	Unknown status	NCT01669044		dexmedetomidine;propofol
41	Prospective Multicenter Validation of a Clinicoradiological Score for Predicting the Severity of Strangulated Small Bowel Occlusion	Unknown status	NCT01125280
42	The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO	Unknown status	NCT02639195
43	The BCAE Study: Best Care for Abdominal Emergencies	Unknown status	NCT04577339
44	Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction: a Multicentre, Prospective, Open Label, Cohort Study	Unknown status	NCT01997684
45	Prospective Nationwide Audit of the Management of Adhesive Small Bowel Obstruction: a Snapshot Study	Unknown status	NCT03786159
46	Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation	Unknown status	NCT01934283
47	Laparoscopic Versus Open Adhesiolysis for Small Bowel Obstruction - A Multicenter, Prospective, Randomized, Controlled Trial	Unknown status	NCT01867528
48	A Feasibility Study of Elemental Diet as an Alternative to Parenteral Nutrition for Patients With Inoperable Malignant Bowel Obstruction	Unknown status	NCT03150992
49	Nasogastric Tube Clamping Trial: Is it Useful? A Proposed Algorithm for Removal.	Unknown status	NCT04001985
50	Ultrasound Emergency Diagnosis of Small Bowel Obstruction. An Observational Study	Unknown status	NCT03226665

Search NIH Clinical Center for Intestinal Obstruction

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Heavy mineral oil

Mineral Oil

Mineral Oil, Light

MINERAL OIL,EXTRA HEAVY

MINERAL OIL,MEDIUM

MINERAL OIL,REFINED

Cochrane evidence based reviews: intestinal obstruction

Sources

Genetic Tests for Intestinal Obstruction

Genetic tests related to Intestinal Obstruction:

#	Genetic test	Affiliating Genes
1	Intestinal Obstruction ²⁸

Sources

Anatomical Context for Intestinal Obstruction

Organs/tissues related to Intestinal Obstruction:

MalaCards : Kidney, Small Intestine, Colon, Pancreas, Appendix, Lymph Node, Liver

Sources

Publications for Intestinal Obstruction

Articles related to Intestinal Obstruction:

(show top 50) (show all 12644)

#	Title	Authors	PMID	Year
1	Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction. ⁵	Ravenscroft G...Laing NG	29781137	2018
2	Familial visceral myopathy diagnosed by exome sequencing of a patient with chronic intestinal pseudo-obstruction. ⁵	Holla OL...Isfoss BL	24777424	2014
3	Segregation of a missense variant in enteric smooth muscle actin γ-2 with autosomal dominant familial visceral myopathy. ⁵	Lehtonen HJ...Tuupanen S	22960657	2012
4	Update on SLC26A3 mutations in congenital chloride diarrhea. ⁵	Wedenoja S...Kere J	21394828	2011
5	Primary 'False' Enterolith: A rare cause of small bowel obstruction. ⁴¹	Salpekar R...Rodrigues G	36407705	2022
6	Colonic obstruction secondary to lithobezoar in a child. ⁴¹	Mouloua AE	36405655	2022
7	Comment on "Do biomarkers have predictive value in the treatment modality of the patients diagnosed with bowel obstruction?" ⁴¹	Cao S...Wang Y	36417634	2022
8	Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. ⁵³ ⁶²	Kukavica-Ibrulj I...Levesque RC	18782827	2008
9	Impact of nutrition on phenotype in CFTR-deficient mice. ⁵³ ⁶²	Cottart CH...Bonora M	17805210	2007
10	Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. ⁵³ ⁶²	Blackman SM...Cutting GR	17030173	2006
11	Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. ⁵³ ⁶²	Guilbault C...Radzioch D	16418321	2006
12	Distal intestinal obstruction syndrome in adults with cystic fibrosis. ⁵³ ⁶²	Dray X...Hubert D	15181619	2004
13	Liver cirrhosis and portal hypertension in cystic fibrosis. ⁵³ ⁶²	Efrati O...Bujanover Y	14501614	2003
14	Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice. ⁵³ ⁶²	Shen L...Westphal H	11774071	2002
15	Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. ⁵³ ⁶²	Ameen N...Salas P	10959824	2000
16	[Gastrointestinal complications of adult patients with cystic fibrosis]. ⁵³ ⁶²	Bargon J...Wagner TO	10494610	1999
17	Clinical and genetic risk factors for cystic fibrosis-related liver disease. ⁵³ ⁶²	Wilschanski M...Kerem E	9917439	1999
18	Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. ⁵³ ⁶²	Rozmahel R...Tsui LC	8589719	1996
19	Useful classification of intussusception for preoperative 3D-MDCT images, type M or W: a case report and a novel classification. ⁶²	Haraoka Y...Amagai T	36439929	2023
20	High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification. ⁶²	Mastromatteo S...Strug LJ	36386424	2023
21	Hand-Sewn Versus Stapled Small Bowel Anastomoses in Patients With Secondary Mesenteric Ischemia. ⁶²	Brillantino A...Castriconi M	36115149	2023
22	Hyperglycaemia and the risk of post-surgical adhesion. ⁶²	Ferns GA...Arjmand MH	32536284	2022
23	Prevention of peritoneal adhesions formation by core-shell electrospun ibuprofen-loaded PEG/silk fibrous membrane. ⁶²	Nadri S...Mostafavi H	35296208	2022
24	Acute abdomen due to strangulated intravesical hernia with incidental finding of kidney tumor: A case report and literature review. ⁶²	Stanisic V...Stanisic B	36453785	2022
25	Costs Associated With Surgical Infections at a Tertiary Referral Hospital in Rwanda. ⁶²	Katabogama JB...Rickard J	35964487	2022
26	From abdominal pain to a diagnosis of primary sclerosing encapsulating peritonitis and its management, a case report. ⁶²	Mekann Bouv-Hez M...Christou N	33502964	2022
27	Comparison of the Effectiveness of Transnasal Humidified Rapid Insufflation Ventilator Exchange (THRIVE) with Facemask Pre-Oxygenation in 40 Patients ≥65 Years of Age Undergoing General Anaesthesia During Gastrointestinal Surgery for Intestinal Obstruction. ⁶²	Wang W...Wang X	36461619	2022
28	Idiopathic anomalous congenital band causing small intestinal obstruction in a 5-month-old dog. ⁶²	Pyne C...Loehr CV	36467375	2022
29	A rare cause of acute intestinal obstruction: Ileo-sigmoid knotting type IIA. ⁶²	Alsuhaimi MA...Alghamdi AA	36389199	2022
30	Colonic sand impaction with cecal rupture and peritonitis in an adult African savanna elephant, and review of noninfectious causes of gastrointestinal disease in elephants. ⁶²	Teodoro TGW...Asin J	36401512	2022
31	Laparoscopic Welti's Maneuver: A Single-Center Experience. ⁶²	Zuin M...Fiscon V	36445742	2022
32	Innovative Endoscopic Management of a Duodenal Web Using Balloon Dilatation and a Gastrojejunal Tube in an Infant with Complex Esophageal Atresia. ⁶²	Kueppers J...Muensterer O	36445752	2022
33	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. ⁶²	Jing C...Deng W	35304622	2022
34	[Risk factor and nomogram for predicting the probability of a permanent stoma after laparoscopic intersphincteric resection for ultralow rectal cancer]. ⁶²	Hu G...Tang JQ	36396375	2022
35	[Effect of intestinal obstruction stent combined with neoadjuvant chemotherapy on the pathological characteristics of surgical specimens in patients with complete obstructive colorectal cancer]. ⁶²	Cao K...Han JG	36396377	2022
36	Spontaneous Ogilvie's Syndrome in a Nonagenarian Male: A Study of a Rare Case With Literature Review. ⁶²	Hussain F...Khurshid N	36475136	2022
37	Left-Sided Colonic Tuberculosis Presenting as Colonic Stricture: A Rare Presentation of a Common Disease. ⁶²	Abdul Jabbar S...Hussain S	36447761	2022
38	Large Bowel Obstruction Secondary to a Fecaloma in a Child With Cerebral Palsy. ⁶²	Ul Haq S	36475161	2022
39	Redo Gastric Bypass following internal herniation with gangrenous roux limb, in second trimester pregnancy: How safe? ⁶²	Das SS...Bandok WZM	36270206	2022
40	A 10 cm pedunculated duodenal Brunner gland hamartoma, case report and literature review. ⁶²	Alsugair Z...Chassagne L	36270207	2022
41	Filiform polyposis presenting with rapid growth and severe anemia case report. ⁶²	Alkhuzaie A...Aldosari M	36334548	2022
42	Meckel's diverticulum causing acute intestinal obstruction: A case series. ⁶²	Bhattarai HB...Priya A	36381041	2022
43	Imaging congenital anomalies of the ileum in adults:a pictorial review. ⁶²	Ghahremani GG	36401130	2022
44	[Current status of influencing factors for postoperative anastomotic leakage in low rectal cancer]. ⁶²	Liu YT...Wang GY	36396382	2022
45	Adult sigmoidorectal intussusception as an unexpected cause of lower gastrointestinal bleeding. ⁶²	Pinerua-Gonsalvez JF...Zambrano-Infantino RDC	36412482	2022
46	Intestinal occlusion due to Burkitt lymphoma: an unusual cause. ⁶²	Sierra Gabarda O...Fernandez Bonilla EM	35607925	2022
47	Blue rubber bleb nevus syndrome complicated with disseminated intravascular coagulation and intestinal obstruction: A case report. ⁶²	Zhai JH...Wang BM	36405278	2022
48	Effect of accelerated rehabilitation combined with enteral nutrition on gastrointestinal function recovery after hepatectomy. ⁶²	Qiu J...Wang Y	35904638	2022
49	Embryology and anatomy of Hirschsprung disease. ⁶²	Hei Ha JL...Hang Tam PK	36417785	2022
50	Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq. ⁶²	Zhang D...Zhuo Z	36424614	2022

Sources

Genes for Intestinal Obstruction

Genes related to Intestinal Obstruction (1 elite genes):

(show all 39)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	SLC26A3	Solute Carrier Family 26 Member 3	Protein Coding	405.53	Pathogenic ⁵ DISEASES inferred ¹⁴	21394828
2	ACTG2	Actin Gamma 2, Smooth Muscle	Protein Coding	30.25	Likely pathogenic ⁵ DISEASES inferred ¹⁴	29781137 22960657 24777424
3	GDNF	Glial Cell Derived Neurotrophic Factor	Protein Coding	17.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	11774071
4	GUCY2C	Guanylate Cyclase 2C	Protein Coding	14.26	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
5	EDNRB	Endothelin Receptor Type B	Protein Coding	13.92	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
6	RET	Ret Proto-Oncogene	Protein Coding	13.89	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
7	KRT7	Keratin 7	Protein Coding	13.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	CDX2	Caudal Type Homeobox 2	Protein Coding	13.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	EDN3	Endothelin 3	Protein Coding	13.26	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
10	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	13.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	CD8A	CD8a Molecule	Protein Coding	13.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	KRT20	Keratin 20	Protein Coding	12.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	CFTR	CF Transmembrane Conductance Regulator	Protein Coding	12.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17030173 8589719 9917439 (more) 17805210 18782827 10959824 14501614 10494610 15181619 16418321
14	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	12.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	NRTN	Neurturin	Protein Coding	12.24	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
16	FLNA	Filamin A	Protein Coding	11.64	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
17	SGO1	Shugoshin 1	Protein Coding	11.06	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
18	MSRA	Methionine Sulfoxide Reductase A	Protein Coding	10.57	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	MVK	Mevalonate Kinase	Protein Coding	10.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	CRP	C-Reactive Protein	Protein Coding	7.93	DISEASES inferred ¹⁴
21	ALB	Albumin	Protein Coding	7.74	DISEASES inferred ¹⁴
22	BLVRB	Biliverdin Reductase B	Protein Coding	7.44	GeneCards inferred via : Publications (show sections)
23	HDC	Histidine Decarboxylase	Protein Coding	7.44	GeneCards inferred via : Publications (show sections)
24	PDPK1	3-Phosphoinositide Dependent Protein Kinase 1	Protein Coding	7.44	GeneCards inferred via : Publications (show sections)
25	WWTR1	WW Domain Containing Transcription Regulator 1	Protein Coding	7.44	GeneCards inferred via : Publications (show sections)
26	YAP1	Yes1 Associated Transcriptional Regulator	Protein Coding	7.44	GeneCards inferred via : Publications (show sections)
27	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	7.34	DISEASES inferred ¹⁴
28	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	7.31	DISEASES inferred ¹⁴
29	MLN	Motilin	Protein Coding	7.19	DISEASES inferred ¹⁴
30	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.1	DISEASES inferred ¹⁴
31	TCF21	Transcription Factor 21	Protein Coding	7.01	DISEASES inferred ¹⁴
32	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	6.9	DISEASES inferred ¹⁴
33	IL6	Interleukin 6	Protein Coding	6.88	DISEASES inferred ¹⁴
34	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	6.82	DISEASES inferred ¹⁴
35	SLC26A9	Solute Carrier Family 26 Member 9	Protein Coding	6.8	DISEASES inferred ¹⁴
36	TNF	Tumor Necrosis Factor	Protein Coding	6.72	DISEASES inferred ¹⁴
37	CD34	CD34 Molecule	Protein Coding	6.65	DISEASES inferred ¹⁴
38	ANO1	Anoctamin 1	Protein Coding	6.63	DISEASES inferred ¹⁴
39	F2	Coagulation Factor II, Thrombin	Protein Coding	6.52	DISEASES inferred ¹⁴

Sources

Variations for Intestinal Obstruction

ClinVar genetic disease variations for Intestinal Obstruction:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	SLC26A3	NM_000111.3(SLC26A3):c.1000G>T (p.Glu334Ter)	SNV	Pathogenic	978618	rs1208952914	GRCh37: 7:107423769-107423769 GRCh38: 7:107783324-107783324
2	SLC26A3	NM_000111.3(SLC26A3):c.269_270dup (p.Gly91fs)	DUP	Pathogenic	55994	rs386833476	GRCh37: 7:107434187-107434188 GRCh38: 7:107793742-107793743
3	ACTG2	NM_001615.4(ACTG2):c.442C>T (p.Arg148Cys)	SNV	Likely Pathogenic	1177291		GRCh37: 2:74136257-74136257 GRCh38: 2:73909130-73909130
4	ERF	NM_006494.4(ERF):c.1636C>T (p.Arg546Ter)	SNV	Uncertain Significance	599007	rs764412749	GRCh37: 19:42752628-42752628 GRCh38: 19:42248476-42248476
5	GATA4	NM_001308093.3(GATA4):c.94G>C (p.Ala32Pro)	SNV	Uncertain Significance	599008	rs773545065	GRCh37: 8:11565915-11565915 GRCh38: 8:11708406-11708406

Sources

Expression for Intestinal Obstruction

Search GEO for disease gene expression data for Intestinal Obstruction.

Sources

Pathways for Intestinal Obstruction

Pathways related to Intestinal Obstruction according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.02	SGO1 RET NRTN MTOR GDNF FLNA
2	Cytoskeletal Signaling ³	11.95	KRT7 KRT20 FLNA ACTG2
3	RET signaling ⁶⁶ Show member pathways Signaling events regulated by Ret tyrosine kinase ⁶¹	10.69	RET NRTN GDNF

Sources

GO Terms for Intestinal Obstruction

Biological processes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane hyperpolarization	GO:0060081	9.73	SLC26A3 CFTR
2	positive regulation of prostaglandin-endoperoxide synthase activity	GO:0060585	9.71	NOD2 EDN3
3	intracellular pH elevation	GO:0051454	9.67	SLC26A3 CFTR
4	vasoconstriction	GO:0042310	9.63	CRP EDN3 EDNRB
5	vein smooth muscle contraction	GO:0014826	9.62	EDNRB EDN3
6	posterior midgut development	GO:0007497	9.56	RET EDNRB
7	enteric nervous system development	GO:0048484	9.43	RET GDNF EDNRB
8	neural crest cell migration	GO:0001755	9.32	RET NRTN GDNF EDNRB EDN3